Business
Dexcom develops continuous glucose monitoring systems for diabetes and metabolic health.
Dexcom converted continuous-glucose-monitor demand into double-digit growth, high margins and more than $1 billion of free cash flow.
The read at a glance✓ Audited against SEC data
- Growth — Revenue grew 15.6%OK
- Profitability — Net income grew 45.1% to $836.3M from $576.2MOK
- Cash flow — Free cash flow grew 70.8% to $1.077B from $630.7MOK
- Margins — Operating margin expanded 468 bps to 19.56%OK
- Accounting — High-quality diabetes-technology growthNote
- Insiders — 1 purchases and 20 salesOK
Where the revenue comes from
Fiscal 2025, as DEXCOM INC reports it. History and quarterly detail are in the app.
- Sales Channel Through Intermediary$4.0B
- Sales Channel Directly To Consumer$703.0M
Leadership changes
From DEXCOM INC's own filings, the day they're filed.
- Jacob S. Leach · Chief Operating Officer · departureeff. 2026-01-01
- Kevin R. Sayer · Chief Executive Officer · departureeff. 2026-01-01
- Kevin R. Sayer · Chief Operating Officer · departureeff. 2026-01-01
Latest filings
- 10-Q · Quarterly report2026-07-30
- 8-K · Company announcement2026-07-30
- 8-K · Company announcement2026-05-28
- 8-K · Company announcement2026-05-15
- 10-Q · Quarterly report2026-04-30
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about DEXCOM INC, every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.